Patients with atrial fibrillation (AF) undergoing dialysis have a higher risk for stroke and bleeding attributable to platelet and coagulation abnormalities, associated comorbidities, routine heparinization during dialysis, and warfarin-associated vascular calcification. Interestingly, current observational studies on warfarin use and the risk for stroke and bleeding in patients with AF undergoing dialysis found conflicting results and there is a lack of randomized, controlled trials on this issue. To enhance the knowledge on this issue, we conducted a population-based retrospective cohort study of patients aged ≥ 65 years admitted to a hospital with a diagnosis of AF from 1998 to 2007, in Quebec and Ontario, Canada. We observed that dialysis patients (n=1626), in comparison with nondialysis patients (n=204 210), had high risk score for stroke (CHADS2 score ≥ 2: 72.3% versus 54.9%) and bleeding (HAS-BLED score ≥ 3: 84.9% versus 24.6%). We found that in patients with AF undergoing dialysis, warfarin use, in comparison with no-use, was not associated with a lower risk for stroke, but was associated with a 44% higher risk for bleeding event. Thus, the risk-benefit profile does not appear to be favorable for routine warfarin use for the reduction of stroke in patients with AF undergoing dialysis. Because of the observational nature of our study, we propose to conduct a large multicenter randomized, controlled trial to clarify this issue and also to guide AF management guideline bodies around the world. See p 1196.
Aggregate Risk of Cardiovascular Disease Among Adolescents Perinatally Infected With the Human Immunodeficiency Virus
Previous studies of perinatally HIV-infected children and adolescents raised concern about increased or accelerated risk of cardiovascular disease resulting from adverse distributions of individual atherosclerotic risk factors such as hyperlipidemia, insulin resistance, and body fat. For the first time, composite cardiovascular risk scores have been calculated for these HIV-infected youth using the previously validated Pathobiological Determinants of Atherosclerosis in Youth (PDAY) scoring system. These aggregate scores integrate a number of modifiable cardiovascular disease risk factors such as dyslipidemia, smoking, hypertension, obesity, and hyperglycemia. Fortyeight percent and 24% of our youth had high coronary arteries and abdominal aorta PDAY scores, respectively, identifying high-risk youth who may benefit from early lifestyle or clinical interventions. We additionally found HIV disease severity and ritonavir-boosted protease inhibitor use to significantly predict high scores, suggesting that switching to new antiretroviral regimens less likely to cause metabolic abnormalities should be considered for youth with increased atherosclerotic risk factor burden. Finally, our study contributes to growing literature showing increased global risk for premature cardiovascular disease morbidity and mortality in the perinatally HIV-infected population, including risk of cardiomyopathy, leading to heart failure, and risk of cardiometabolic disease, leading to atherosclerotic disease. A comprehensive assessment and treatment plan based on validated screening and interventions may be useful for those at highest cardiovascular disease risk in the perinatally HIV-infected population. See p 1204.
Neurofibromin-Deficient Myeloid Cells Are Critical Mediators of Aneurysm Formation In Vivo
Neurofibromatosis type 1 (NF1) is a common genetic disorder resulting from mutations in the NF1 tumor suppressor gene. Although malignancy and neoplasia are common manifestations of NF1, cardiovascular disease is an underrecognized source of significant morbidity and premature mortality in NF1 patients. NF1 patients have increased propensity for the development of profound arterial disease, including renal and carotid stenosis, aneurysms, and cerebrovascular disease. In this study, we present the first animal model of Nf1 aneurysm formation by using a well-described transgenic mouse line. These Nf1 aneurysms demonstrate increased infiltration of myeloid cells, inflammatory changes, and production of reactive oxygen species, which are characteristic of aneurysms in the general population. Based on these observations, we provide novel evidence that Nf1 aneurysms are significantly reduced by daily, low-dose statin administration and antioxidant therapy, which may be mediated through diminished myeloid cell interactions with the vascular wall and reduced reactive oxygen species production. For the clinician, NF1 represents an important risk factor for multiple forms of cardiovascular disease, and early recognition and treatment may prevent premature mortality in this patient population. See p 1213.
ST-Elevation Myocardial Infarction Diagnosed After Hospital Admission
Time to treatment for ST-elevation myocardial infarction (STEMI) patients presenting to percutaneous coronary intervention (PCI) hospitals has improved dramatically over the past 10 years, particularly for patients using emergency medical services (EMS). Limited data exist regarding the reasons for admission, time to treatment, and clinical outcomes of patients who develop STEMI while in-hospital. We report the reasons for admission, demographic and angiographic characteristics, and clinical outcomes of 83 patients who developed STEMI following admission to the hospital from March 2003 to January 2013. Patients who developed STEMI while in-hospital were older, had a larger body mass index, a higher rate of hypertension, were more likely to have a history of coronary artery disease, and presented more frequently with cardiac arrest or cardiogenic shock, or they were likely to have a Killip class of 2, 3, or 4. Door-to-balloon times (diagnostic ECG-to-balloon for in-hospital patients) were longer than for patients who presented via EMS (76 versus 51 minutes; P<0.001), but similar to self/family-driven patients (76 ver 
Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation: Impact on Late Clinical Outcomes and Left Ventricular Function
The need for permanent pacemaker implantation (PPI) is a frequent complication after transcatheter aortic valve implantation. However, evidence of the clinical impact of PPI after transcatheter aortic valve implantation remains scarce. This study assessed the impact of new PPI after transcatheter aortic valve implantation on late outcomes in a cohort of 1556 patients undergoing balloon-expandable and self-expandable valves. The incidence of 30-day PPI was 15.4%, mostly as a result of complete atrioventricular block. Thirty-day PPI was not associated with all-cause mortality, cardiovascular mortality, and all-cause mortality or rehospitalization for heart failure (P>0.20). Moreover, 30-day PPI was a protective factor for the occurrence of unexpected (sudden or unknown) death (hazard ratio, 0.31; P=0.023). The occurrence of new-onset persistent left bundle-branch block and a lower left ventricular ejection fraction at baseline were independent predictors of sudden cardiac death. 
Activation of CXCR7 Limits Atherosclerosis and Improves Hyperlipidemia by Increasing Cholesterol Uptake in Adipose Tissue
Hypercholesterolemia caused by increased plasma levels of apolipoprotein B-containing lipoproteins, such as low-density lipoprotein or very low-density lipoprotein, drives the pathogenesis of atherosclerosis. Chemokines and their receptors mediate the hypercholesterolemia-induced mobilization and recruitment of monocytes that leads to accumulation of macrophages in atherosclerotic arteries. In contrast to other chemokine receptors, CXCR7 does not induce G-protein-coupled signaling and is not expressed on leukocytes but internalizes and degrades its ligands, such as CXCL12 and CXCL11. We studied the role of CXCR7 and the synthetic CXCR7 ligand CCX771 in mouse models of atherosclerosis. Our results reveal an unanticipated role of CXCR7 in the regulation of circulating very low-density lipoprotein cholesterol levels, which is unrelated to its effects on systemic CXCL12 levels. Treatment with CCX771 lowered very low-density lipoprotein levels in hyperlipidemic mice because of an enhanced uptake into adipose tissue and thus reduced hyperlipidemia-induced monocytosis and atherosclerotic lesion formation. This effect of CCX771 was probably attributable to increased lipoprotein lipase activity in adipose tissue in response to downregulation of Angptl4. Conversely, genetic deficiency of CXCR7 increased serum cholesterol and triglyceride levels and promoted lesion formation after vascular injury in hyperlipidemic mice. Thus, our findings indicate that adipose tissue regulates serum cholesterol levels under hyperlipidemic conditions through CXCR7-mediated uptake of very low-density lipoprotein. This cholesterol-buffering mechanism of adipose tissue may play an important role in the handling of an increased dietary lipid load. Pharmacological activation of CXCR7 can enhance its lipid-lowering effect and may thus provide a novel therapeutic approach to the treatment of atherogenic dyslipidemia. See p 1244.
